News
NWBO
0.166
+9.43%
0.014
Press Release: Northwest Biotherapeutics Announces Expansion of Its Technical Team
Dow Jones · 4h ago
Northwest Biotherapeutics Announces Expansion of Its Technical Team
PR Newswire · 4h ago
Weekly Report: what happened at NWBO last week (1019-1023)?
Weekly Report · 10h ago
Weekly Report: what happened at NWBO last week (1012-1016)?
Weekly Report · 10/19 09:38
Weekly Report: what happened at NWBO last week (1005-1009)?
Weekly Report · 10/12 09:40
Northwest Biotherapeutics, NHSBT partners to expand DCVax-L production
Seeking Alpha · 10/08 21:10
Weekly Report: what happened at NWBO last week (0928-1002)?
Weekly Report · 10/05 09:40
Weekly Report: what happened at NWBO last week (0921-0925)?
Weekly Report · 09/28 09:38
Weekly Report: what happened at NWBO last week (0914-0918)?
Weekly Report · 09/21 09:38
Weekly Report: what happened at NWBO last week (0907-0911)?
Weekly Report · 09/14 09:40
Weekly Report: what happened at NWBO last week (0831-0904)?
Weekly Report · 09/07 09:37
Weekly Report: what happened at NWBO last week (0824-0828)?
Weekly Report · 08/31 09:41
Weekly Report: what happened at NWBO last week (0817-0821)?
Weekly Report · 08/24 09:41
Weekly Report: what happened at NWBO last week (0810-0814)?
Weekly Report · 08/17 09:42
NORTHWEST BIOTHERAPEUTICS, INC. FORM 10-Q
Press release · 08/15 07:44
Weekly Report: what happened at NWBO last week (0803-0807)?
Weekly Report · 08/10 09:39
Northwest Biotherapeutics enters MOU for collaboration with SPIMACO
TipRanks · 08/06 16:06
Weekly Report: what happened at NWBO last week (0727-0731)?
Weekly Report · 08/03 09:39
Northwest Biotherapeutics Secures New Convertible Note Financing
TipRanks · 07/31 21:52
Weekly Report: what happened at NWBO last week (0720-0724)?
Weekly Report · 07/27 09:41
More
Webull provides a variety of real-time NWBO stock news. You can receive the latest news about Northwest Bio through multiple platforms. This information may help you make smarter investment decisions.
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.